Glaucoma is the leading cause of irreversible blindness, affecting around 80 million people
worldwide. Glaucoma is a multifactorial disease of poorly understood pathogenesis, with …

Abstract The Icare HOME (TA022, Icare Oy, Vanda, Finland) is rebound tonometer recently
approved by the US Food and Drug Administration in March 2017 designed for self …

Purpose Ocular diurnal rhythms have been implicated in myopia, glaucoma, diabetes, and
other ocular pathologies. Ocular rhythms have been well described in adults; however, they …

Purpose The aim of this study was to investigate the safety and performance of the second
generation of an implantable intraocular pressure (IOP) sensor in patients with primary open …

The rebound tonometer has a unique mechanism for measuring intraocular pressure (IOP)
and has become popular worldwide due to its ease of use. The most notable advantages …

Purpose To evaluate the Icare HOME (TA022) device (Icare Oy, Vanda, Finland) for use by
glaucoma patients for self-tonometry. Design Prospective performance evaluation of a …

Objective Our aim was to assess the acceptability and feasibility of iCare HOME tonometer
(HT) and Virtual Field (VF) devices in the home monitoring of glaucoma. Design Prospective …

The future of intraocular lens (IOL) technology has already begun with a number of recent
innovations. The postoperative change of refractive power will lead to a customized fine …

The coronavirus disease 2019 pandemic drastically impacted global health, forcing
institutions to provide alternative models of safe and reliable health care. In this context …

Glaucoma is a common optic neuropathy that can lead to irreversible vision loss, and
intraocular pressure (IOP) is the only known modifiable risk factor. The primary method of …